Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SA Transcripts 162.16K Followers Follow Sana Biotechnology, Inc. ( SANA ) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 1:40 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Steven Harr President, CEO & Director We'll kind of level-set. And... Samantha Semenkow Citigroup Inc., Research Division You can add '27, if you'd like. Steven Harr President, CEO & Director Yes. So first of all, I think most people here recognize we'll make forward-looking statements. So feel free to take a look at our 10-Q for risk factors. So we've been working hard for a while on developing 2 different important -- what we think could be important platforms. One is what we call our hypoimmune platform. And that has the goal of hiding allogeneic cells from immune recognition. And it gives us a chance to really scale the use of cell therapy broadly. And our primary asset has been this drug we call SC451, which is in development, for people with type 1 diabetes. And our goal is very simple. It's a functional cure. It is 1 injection of cells that will lead to normal blood sugars or euglycemia, with no immunosuppression, for life for these patients. We can go into why that might work as we chat. But we have made a lot of progress. We've shown that the technology works in a different setting, which is cadaveric-derived islets, which is less scalable. So we really want to develop a real drug. And we're very close to being able to figure this out. We've been working hard this year on an IND and hopefully beginning our clinical trial. And happy to say that so far, so good. So there are 3 really important parts of getting an IND ready. One is